## Management of Severe TEN with Progression Despite Supportive Care ### Clinical Context This patient has **Toxic Epidermal Necrolysis (TEN)** with: - ≥30% BSA involvement (45% in this case) - Rapid progression despite drug withdrawal and supportive care - Active disease (new lesions appearing) These features indicate **severe, refractory TEN** requiring adjunctive immunomodulatory therapy. ### Pathophysiology of TEN Progression TEN is driven by massive CD8+ T-cell infiltration and keratinocyte apoptosis. Continued disease activity despite drug removal suggests ongoing immune activation requiring targeted intervention. ### Evidence-Based Adjunctive Therapy for Severe TEN | Agent | Mechanism | Evidence | Role | |---|---|---|---| | **IVIG** | Blocks Fas-FasL interaction; inhibits T-cell activation | Multiple case series; some RCT support | **First-line adjunctive agent for severe TEN** | | **Systemic corticosteroids** | Anti-inflammatory | Controversial; meta-analyses show no mortality benefit | Avoid as monotherapy; may increase infection | | **Cyclosporine** | T-cell immunosuppression | Emerging evidence; small case series | Alternative if IVIG unavailable | | **Plasmapheresis** | Removes circulating immune mediators | Limited evidence; rarely used | Not standard; reserved for extreme cases | ### High-Yield: IVIG in Severe TEN **Key Point:** IVIG is the **preferred adjunctive agent** for TEN with: - ≥30% BSA involvement, OR - Rapid progression despite drug withdrawal, OR - High-risk features (age >40, malignancy, sepsis) **Mechanism:** IVIG blocks Fas-FasL-mediated keratinocyte apoptosis and suppresses T-cell activation. **Dosing:** 2 g/kg IV over 3–5 days (may repeat if no response in 48–72 hours). **Clinical Pearl:** IVIG has been shown in case series and small RCTs to arrest disease progression and reduce mortality in severe TEN. It is now considered standard adjunctive therapy alongside supportive care. ### Treatment Algorithm for This Patient ```mermaid flowchart TD A[TEN 45% BSA, progressive despite drug withdrawal]:::outcome A --> B[Supportive care established?]:::decision B -->|Yes| C[Add IVIG 2 g/kg IV over 3-5 days]:::action C --> D[Reassess in 48-72 hours]:::decision D -->|Improvement| E[Continue supportive care + monitoring]:::action D -->|No response| F[Consider cyclosporine or plasmapheresis]:::action B -->|No| G[Optimize fluids, infection control, eye care]:::action G --> C ``` [cite:Harrison 21e Ch 56; Robbins 10e Ch 25] --- ## Why Each Distractor Is Wrong **Systemic corticosteroids (Option 1):** - Systemic corticosteroids are **not recommended as first-line or primary adjunctive therapy** for TEN. - Meta-analyses have shown no mortality benefit and potential for increased infection risk in TEN. - While some clinicians use low-dose corticosteroids as adjunctive agents in severe cases, IVIG is preferred. - High-dose corticosteroids (2 mg/kg/day) in TEN increase risk of secondary infection and sepsis without proven benefit. **Plasmapheresis (Option 2):** - Plasmapheresis has **limited evidence** in TEN and is not standard therapy. - It is occasionally used in extreme, rapidly progressive cases, but IVIG is the preferred first-line adjunctive agent. - Plasmapheresis is invasive, requires vascular access, and carries risks of electrolyte disturbance and infection. - No robust RCT evidence supports plasmapheresis over IVIG in TEN. **Topical tacrolimus (Option 3):** - Topical tacrolimus is useful for **localized skin involvement or post-TEN erythema multiforme**, not for active, rapidly progressive TEN. - In severe systemic TEN with 45% BSA involvement, topical agents alone are insufficient. - Topical therapy does not address the underlying systemic immune pathology driving keratinocyte apoptosis. - Systemic immunomodulation (IVIG) is required for this clinical scenario.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.